Intervention in autoimmunity: The potential of vitamin D receptor agonists
Intervention in autoimmunity: The potential of vitamin D receptor agonists
复制标题
DOI：
10.1016/j.cellimm.2005.04.013
复制
发表时间：
2005-02-01
影响因子：
4.3
通讯作者：
Adorini, L
中科院分区：
文献类型：
--
作者：
Adorini, L
维生素D受体（VDR）激动剂因其控制钙代谢和调节多种细胞类型的生长和分化的能力而闻名。最近，VDR激动剂具有免疫调节特性，特别是显著的促耐受性活性。VDR激动剂可以直接作用于T细胞，但dc似乎是它们的主要目标。VDR激动剂调节DC和T细胞功能的能力是由两种细胞类型中的VDR表达以及它们的信号转导途径中共同靶点的存在介导的，例如apc和T细胞中被VDR激动剂下调的核因子nf - κ B。VDR激动剂的一个潜在的非常重要的活性是它们在体外和体内诱导耐受性dc的能力，这些dc能够增强CD4(+)CD25（+）抑制性T细胞，进而抑制Th1细胞的反应。这些作用机制可以解释VDR激动剂在治疗th1介导的自身免疫性疾病中的一些免疫调节特性，但也可能代表VDR介导的先天和适应性免疫反应调节的生理因素。(c) 2005爱思唯尔公司版权所有。
Vitamin D receptor (VDR) agonists are well known for their capacity to control calcium metabolism and to regulate growth and differentiation of many cell types. More recently, it has become clear that VDR agonists possess immunoregulatory properties and, in particular, pronounced pro-tolerogenic activities. VDR agonists can act directly on T cells, but DCs appear to be their primary targets. The capacity of VDR agonists to modulate DC and T cell functions is mediated by VDR expression in both cell types and by the presence of common targets in their signal transduction pathways, such as the nuclear factor NF-kappa B that is downregulated by VDR agonists in APCs and in T cells. A potentially very important activity of VDR agonists is their capacity to induce in vitro and in vivo tolerogenic DCs able to enhance CD4(+)CD25(+) suppressor T cells that, in turn, inhibit Th1 cell responses. These mechanisms of action can explain some of the immunoregulatory properties of VDR agonists in the treatment of Th1-mediated autoimmune diseases, but may also represent a physiologic element in the VDR-mediated regulation of innate and adaptive immune responses. (c) 2005 Elsevier Inc. All rights reserved.